Cargando…
Calcineurin inhibition protects against dopamine toxicity and attenuates behavioral decline in a Parkinson’s disease model
BACKGROUND: Parkinson’s disease (PD), a highly prevalent neuro-motor disorder is caused due to progressive loss of dopaminergic (DAergic) neurons at substantia nigra region of brain. This leads to depleted dopamine (DA) content at striatum, thus affecting the fine tuning of basal ganglia. In patient...
Autores principales: | Mondal, Rupsha, Banerjee, Chayan, Nandy, Sumangal, Roy, Moumita, Chakraborty, Joy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394860/ https://www.ncbi.nlm.nih.gov/pubmed/37528492 http://dx.doi.org/10.1186/s13578-023-01068-6 |
Ejemplares similares
-
USP14 as a Therapeutic Target Against Neurodegeneration: A Rat Brain Perspective
por: Banerjee, Chayan, et al.
Publicado: (2020) -
Corrigendum: USP14 as a therapeutic target against neurodegeneration: a rat brain perspective
por: Banerjee, Chayan, et al.
Publicado: (2023) -
Polymorphisms in dopamine‐associated genes and cognitive decline in Parkinson's disease
por: Bäckström, D., et al.
Publicado: (2017) -
The Coordinated Action of Calcineurin and Cathepsin D Protects Against α-Synuclein Toxicity
por: Aufschnaiter, Andreas, et al.
Publicado: (2017) -
Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease
por: Shin, Seunghyeon, et al.
Publicado: (2019)